Crawford Lake Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Crawford Lake Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-57,974	Closed	-$9.85M	–	108
2018 Q2	$9.85M	Sell	57,974 -31,255	-35%	-$4.84M	1.72%	17
2018 Q1	$14.5M	Buy	89,229 +27,889	+45%	+$4.56M	3.1%	8
2017 Q4	$9.19M	Sell	61,340 -54,707	-47%	-$8.1M	2.17%	18
2017 Q3	$17.6M	Buy	+116,047	New	+$17.5M	6.32%	2
2017 Q2	–	Sell	-92,472	Closed	-$10.1M	–	145
2017 Q1	$10.1M	Buy	+92,472	New	+$8.14M	4.01%	4

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crawford Lake Capital Management's VRTX Position: Q3 2018 in Review

Crawford Lake Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 57,974 shares — an estimated $9.85M sold.

Crawford Lake Capital Management first reported a position in VRTX in Q1 2017 and held it in 5 quarters. The position peaked at $17.6M in Q3 2017. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Crawford Lake Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Crawford Lake Capital Management sold 57,974 Vertex Pharmaceuticals shares in Q3 2018, an estimated $9.85M.
Crawford Lake Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Crawford Lake Capital Management's Vertex Pharmaceuticals position peaked at $17.6M in Q3 2017.
697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Crawford Lake Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.